Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

BACKGROUND: Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belinostat combined with CHOP (Bel-CHOP). Secondary objectives included safety/tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Patrick B., Cashen, Amanda F., Nikolinakos, Petros G., Beaven, Anne W., Barta, Stefan Klaus, Bhat, Gajanan, Hasal, Steven J., De Vos, Sven, Oki, Yasuhiro, Deng, Changchun, Foss, Francine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893947/
https://www.ncbi.nlm.nih.gov/pubmed/33602316
http://dx.doi.org/10.1186/s40164-021-00203-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893947/
https://www.ncbi.nlm.nih.gov/pubmed/33602316
http://dx.doi.org/10.1186/s40164-021-00203-8

Ejemplares similares